Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for NVO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 547.31M
March 31, 2026 375.84M
December 31, 2025 1.083M
September 30, 2025 7.514M
June 30, 2025 6.270M
March 31, 2025 195.82M
December 31, 2024 6.118B
September 30, 2024 330.31M
June 30, 2024 -3.924B
March 31, 2024 412.83M
December 31, 2023 1.416B
September 30, 2023 890.65M
June 30, 2023 1.285B
March 31, 2023 749.44M
December 31, 2022 1.026B
September 30, 2022 625.47M
June 30, 2022 1.076B
March 31, 2022 675.01M
December 31, 2021 1.168B
September 30, 2021 561.39M
June 30, 2021 881.75M
March 31, 2021 479.39M
December 31, 2020 893.24M
September 30, 2020 472.69M
June 30, 2020 814.94M
Date Value
March 31, 2020 396.64M
December 31, 2019 731.08M
September 30, 2019 428.49M
June 30, 2019 690.50M
March 31, 2019 448.64M
December 31, 2018 651.98M
September 30, 2018 553.60M
June 30, 2018 543.14M
March 31, 2018 715.28M
December 31, 2017 732.80M
September 30, 2017 655.38M
June 30, 2017 557.57M
March 31, 2017 608.51M
December 31, 2016 599.07M
September 30, 2016 535.20M
June 30, 2016 547.95M
March 31, 2016 554.91M
December 31, 2015 633.15M
September 30, 2015 763.02M
June 30, 2015 587.14M
March 31, 2015 573.27M
December 31, 2014 647.09M
September 30, 2014 706.25M
June 30, 2014 630.07M
March 31, 2014 626.47M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
AstraZeneca PLC 600.99M
Johnson & Johnson -138.00M
Eli Lilly & Co. 1.601B
Merck & Co., Inc. 714.00M
Novartis AG 1.184B